130 related articles for article (PubMed ID: 14568412)
1. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
[TBL] [Abstract][Full Text] [Related]
2. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.
Kovár M; Strohalm J; Ulbrich K; Ríhová B
J Drug Target; 2002 Feb; 10(1):23-30. PubMed ID: 11996083
[TBL] [Abstract][Full Text] [Related]
4. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.
Kovar M; Tomala J; Chmelova H; Kovar L; Mrkvan T; Joskova R; Zakostelska Z; Etrych T; Strohalm J; Ulbrich K; Sirova M; Rihova B
Cancer Res; 2008 Dec; 68(23):9875-83. PubMed ID: 19047168
[TBL] [Abstract][Full Text] [Related]
5. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.
Tomala J; Chmelova H; Strohalm J; Ulbrich K; Sirova M; Rihova B; Kovar M
Int J Cancer; 2011 Oct; 129(8):2002-12. PubMed ID: 21165950
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
[TBL] [Abstract][Full Text] [Related]
8. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy.
St'astný M; Plocová D; Etrych T; Kovár M; Ulbrich K; Ríhová B
J Control Release; 2002 May; 81(1-2):101-11. PubMed ID: 11992683
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
[TBL] [Abstract][Full Text] [Related]
11. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line.
Kunath K; Kopecková P; Minko T; Kopecek J
Eur J Pharm Biopharm; 2000 Jan; 49(1):11-5. PubMed ID: 10613922
[TBL] [Abstract][Full Text] [Related]
12. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.
O'Hare KB; Duncan R; Strohalm J; Ulbrich K; Kopeckova P
J Drug Target; 1993; 1(3):217-29. PubMed ID: 8069563
[TBL] [Abstract][Full Text] [Related]
13. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.
Kovár M; Kovár L; Subr V; Etrych T; Ulbrich K; Mrkvan T; Loucká J; Ríhová B
J Control Release; 2004 Sep; 99(2):301-14. PubMed ID: 15380639
[TBL] [Abstract][Full Text] [Related]
14. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
[TBL] [Abstract][Full Text] [Related]
15. HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia.
St'astný M; Plocová D; Etrych T; Ulbrich K; Ríhová B
Eur J Cancer; 2002 Mar; 38(4):602-8. PubMed ID: 11872356
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
17. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
18. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs.
Ríhová B; Strohalm J; Kubácková K; Jelínková M; Hovorka O; Kovár M; Plocová D; Sírová M; St'astný M; Rozprimová L; Ulbrich K
J Control Release; 2002 Jan; 78(1-3):97-114. PubMed ID: 11772452
[TBL] [Abstract][Full Text] [Related]
19. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens.
Jelínková M; Strohalm J; Plocová D; Subr V; St'astný M; Ulbrich K; Ríhová B
J Control Release; 1998 Mar; 52(3):253-70. PubMed ID: 9743446
[TBL] [Abstract][Full Text] [Related]
20. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
